Clinical trials: Glucose Metabolism
Cardiometabolic Disease
Metagenomics and Integrative Systems Medicine of Cardiometabolic Diseases
Supported by state-of-the-art systems medicine competences including integrative computational and functional genomics, the overarching goal of the trial is to investigate the impact of qualitative and quantitative changes in the…
- Trial name
- METACARDIS (NCT02059538)
- Testing
- Adipose tissue biopsies (omental and subcutaneous) liver, CT-scan, Stools sampling
- Where
- 3 sites in Denmark, France and 1 more
- Volunteers
- 2,350 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Diabetes Mellitus, Type 2, Patient Discharge
Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin
Diabetes is present in 25% of hospitalized patients; yet effective hospital discharge programs for patients with diabetes are understudied.
- Conditions
- Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low, Blood Glucose, High
- Trial name
- NCT03455985
- Testing
- Discharge Order Set (DOS), Enhanced Standard Care (ESC)
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Ohio State University
Type 2 Diabetes
A Study of LY3437943 in Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of…
- Trial name
- NCT04867785
- Testing
- LY3437943, Dulaglutide
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Cystic Fibrosis Related Diabetes
Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)
The study aims to test whether use of CFTR modulators (ETI) improves fasting and post prandial glycemia by enhancing disposition index (DI) in individuals with CFRD with CFTR +ve mutation (at least one copy of F508del) on CFTR…
- Trial name
- NCT07102043
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Diabetes, Brown Adipose Tissue
Brown Fat as Therapeutic Strategy for Obesity and Associated Metabolic Diseases Via Functional Food/Nutraceutical Approach - Molecular Mechanisms of Pentacyclic Triterpenes (BRACE)
To examine MA (Maslinic Acid) safety and efficacy in ameliorating insulin resistance and the cardinal features of metabolic syndrome.
- Trial name
- NCT06484543
- Testing
- Maslinic Acid
- Where
- Singapore
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institute for Human Development and Potential (IHDP), Singapore
Type 2 Diabetes Mellitus
Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes
Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus.
- Trial name
- NCT00103935
- Testing
- Exenatide LAR
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Diabetes Mellitus, Type 1
Post Approval Study of the Eversense® Continuous Glucose Monitoring
A Post Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System over repeat insertion and removal cycles and to demonstrate the long-term safety of the…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PAS (NCT03908125)
- Testing
- Eversense® CGM System
- Where
- 17 sites in United States
- Volunteers
- 273 people
- Sponsor
- Senseonics, Inc.
Diabetes, Hypertension
FFA Hypertension and Inflammation in Lean and Obese Subjects
Although a large number of obese patients develop high blood pressure, the cause is unknown. The purpose of this study is to look at the effect of high fatty acids (a type of fat) in the development of high blood pressure in…
- Conditions
- Diabetes, Hypertension, Obesity
- Trial name
- FFAADA (NCT00721617)
- Testing
- Intralipid 20%, Normal Saline, Oral fat load
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Emory University
Cardiovascular Disease
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and…
- Trial name
- NCT07214857
- Where
- United States
- Volunteers
- 1,385 people
- Sponsor
- Novartis Pharmaceuticals
PreDiabetes
Effect of Phytoecdysterone Administration in Subjects With Prediabetes
Prediabetes is the term used for people whose glucose levels do not meet the criteria for diabetes but are too high to be considered normal.
- Trial name
- NCT03906201
- Testing
- Ecdysterone
- Where
- Mexico
- Volunteers
- 34 people
- Sponsor
- University of Guadalajara
Diabetic Neuropathy
Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy
This study will determine the type and combination of exercise needed to rehabilitate the neuro-compromised diabetic Veteran. Guided exercise protocols may prove to be practical therapeutic options for the prophylactic management…
- Trial name
- NCT00955201
- Testing
- Exercise
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- VA Office of Research and Development
Insulin Resistance, Metabolic Syndrome X
Side Effects of Antipsychotic Medications
Medications like olanzapine have been associated with the development of weight gain and diabetes in some patients. It is not known if the increased risk of developing diabetes is a direct effect on insulin or simply related to…
- Conditions
- Insulin Resistance, Metabolic Syndrome X, Schizophrenia and Disorders With Psychotic Features, Mood Disorders
- Trial name
- NCT00363181
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Stanford University
Diabetes Mellitus, Type 2
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes
The purpose of the study is to determine the efficacy of alogliptin compared to placebo when given alone or as add-on therapy to metformin or add-on to pioglitazone (with or without metformin).
- Trial name
- NCT01289119
- Testing
- Alogliptin, Metformin, Pioglitazone
- Where
- 21 sites in China, Hong Kong and 1 more
- Volunteers
- 506 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 1
Effectiveness of a Combined mHealth-CBT Psychological Intervention to Improve Psychological Well-Being in Young Patients With T1D
Type 1 diabetes (T1D) can lead to psychological adjustments that impact the acceptance and management of this health condition, as well as the overall quality of life of patients, especially among the young.
- Trial name
- NCT06450730
- Testing
- Cognitive-Behavioral Therapy: face-to-face + app
- Where
- Spain
- Volunteers
- 122 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Type 2 Diabetes
Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy
The study design of this trial is double blind, parallel-group, randomized, Placebo controlled study.
- Trial name
- T2DM (NCT01805830)
- Testing
- MP513
- Where
- South Korea
- Volunteers
- 189 people
- Sponsor
- Handok Inc.
Prediabetic State
Autoimmune Diabetes Accelerator Prevention Trial
The autoimmune diabetes ACCELERATOR PREVENTION TRIAL (adAPT) is based on the accelerator hypothesis. The trial is designed to establish whether metformin, an oral hypoglycaemic agent that is known to reduce insulin demand in type…
- Trial name
- adAPT (NCT02881528)
- Testing
- Metformin Hydrochloride
- Where
- 5 sites in United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Exeter
Type 2 Diabetes, Obesity
Study for Pre-Surgical Weight Loss in Type II Diabetes Patients
The purpose of this study is to determine whether the GI Sleeve is safe and effective in treating Type II diabetes patients
- Trial name
- NCT00791128
- Testing
- GI Liner
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Morphic Medical Inc.
Schizophrenia, Psychosis
Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis
This study aims to evaluate, at long-term, the occurrence of liver disease and cardio-vascular risk, in a sample of patients diagnosed with first episode of non-affective psychosis.
- Conditions
- Schizophrenia, Psychosis, Metabolic Syndrome
- Trial name
- NCT03481465
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Marques de Valdecilla
Type 2 Diabetes Mellitus
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.
Several free fatty acids receptors (FFARs) have been discovered. These have been implicated in metabolic processes and inflammation.
- Trial name
- NCT03305367
- Testing
- Hydrolyzed pine nut oil
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.